Company* |
Funding Institution | Amount (M) |
Type | Details (Date) |
| | ||||
Achillion |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
The grant will support Achillion's program for identifying small-molecule HIV capsid assembly inhibitors, and to further characterize capsid inhibition as an HIV treatment method (5/2) |
Akubio Ltd.* (UK) |
U.S. Army Medical Research Institute of Infectious Diseases |
$3 |
Joint development program |
The parties will use $3M in funding from the U.S. National Institute of Allergy and Infectious Diseases to develop enhanced systems for the detection of bioterrorism agents based on Akubio's acoustic biosensor technology (5/17) |
Alchemia Ltd. |
Australian government |
A$7.8 (US$6) |
Pharmaceuticals Partnerships Program grant |
The grant entitles Alchemia up to A$7.8M over three years for its programs if it meets forecast R&D spending for the period (3/31) |
AlphaVax Inc.* |
National Institute of Allergy and Infectious Diseases |
$6.5 |
Grant |
The three-year award will support the preclinical development of an influenza vaccine using the company's vaccine technology, the AlphaVax replicon vector system (4/18) |
Amarillo |
National Institutes of Health |
$0.104 |
Phase I SBIR grant |
The grant will be used to further develop a vaccine to combat Helicobacter pylori (5/5) |
Angel Biotechnology |
Undisclosed |
£275,000(US$502,595) |
R&D grants |
Two grants will support Rapid Recombination technology and Angel's antiviral antibody program (5/24) |
Atom Sciences |
National Institute of Allergy and Infectious Diseases |
$0.1 |
Phase I SBIR grant |
The grant will support development of a diagnostic tool for tuberculosis using a method called Limited Primer Extension (4/21) |
Biofactura Inc.* |
Maryland Technology Development Corp. |
ND |
TEDCO investment |
The funds will support its collaboration with USAMRIID for develpment of therapeutics for poxviruses (4/21) |
BioPort Corp.* |
Department of Health and Human Services |
$122.7 |
Project BioShield contract |
The contract calls for BioPort to manufacture 5 million doses of anthrax vaccine for use in the federal stockpile (5/6) |
Bolder |
National Institute of Allergy and Infectious Diseases |
$0.99 |
Phase I SBIR grant |
The grant will support work to improve the properties of gamma interferon for stimulating the immune system to fight infections (5/18) |
Callisto |
National Institute of Allergy and Infectious Diseases |
$0.89 |
Biodefense Partnerships grant |
To develop a monoclonal antibody and vaccine against bacterial superantigen toxins, which have potential for use as bio-weapons (4/1) |
Carrington |
National Institute of Allergy and Infectious Diseases |
$0.463 |
Biodefense grant |
Carrington subsidiary DelSite Biotechnologies Inc. will use the second year of funding to continue evaluating its GelVac system to nasally deliver antigens associated with common infectious diseases (4/14) |
CombinatoRx |
National Institute of Allergy and Infectious Diseases |
$4.4 |
Cooperative research grant |
CombinatoRx will get up to $4.4M to discover combinations of approved small-molecule drugs that block the adverse effects of anthrax lethal toxin; it would own resulting products (4/13) |
Crucell NV |
National Institute of Allergy and Infectious Diseases |
$27.6 |
Manufacturing contract |
Crucell will manufacture up to 10 batches of clinical material of the PER.C6-based Ebola vaccine for use in Phase I and early Phase II trials (4/14) |
Crucell NV |
U.S. Department of Health and Human Services |
ND |
Subcontract award |
Crucell partner Sanofi Pasteur was awarded a $97M contract from HHS to develop a PER.C6- based cell-culture influenza vaccine; Crucell is a subcontractor for the work (4/1) |
Dimerix |
AusIndustry (Australia) |
A$0.2 (US$0.15) |
Commercial Ready grant |
The grant will support development of a new class of drugs targeting G protein-coupled receptors (5/11) |
DVC LLC |
U.S. Department of Defense |
$19.6 |
Contract award |
DVC will lead a collaboration that includes Baxter Healthcare Corp. to develop plasma-derived human butyrylcholinesterase for protecting against the toxic effects of certain chemical warfare agents (4/13) |
EpiVax Inc.* |
National Institutes of Health |
$0.6 |
Phase I SBIR grant |
The grant will be used to develop a genome- derived, epitope-driven Helicobacter pylori vaccine (4/27) |
FASgen Inc.* |
National Institutes of Health |
$0.5 |
Grant |
The grant will support completion of final preclinical work for the company's FAS20013 tuberculosis candidate (5/13) |
4SC AG* |
Federal Ministry of Education and Research (Germany) |
€2.9 (US$3.65) |
BioChancePLUS program grant |
The 2.5-year funding will support development of drug candidates for treating autoimmune diseases, particularly multiple sclerosis (5/10) |
Genaera Corp. |
Cystic Fibrosis |
$2.35 |
Therapeutics Development Award |
CFFT is supporting a pivotal Phase II trial in Ireland of Lomucin in CF patients through milestone-driven matching funds (4/18) |
GeneGo Inc.* |
National Institute of Environmental Health Sciences |
ND |
Phase I SBIR grant |
The grant is for the elucidation and analysis of signaling and metabolic networks implicated in cellular response to drugs and toxins (5/24) |
GPC Biotech |
German Ministry for Education and Research |
€2.2 (US$2.8) |
BioChancePLUS program grant |
The funds will support a program to establish proof of concept for the activity of specific kinase inhibitors in animal models covering several disease areas; each company will get €1.1M (4/26) |
Icon Genetics |
Bavarian Research Foundation (Germany) |
ND |
Funding support |
The funding supports a collaboration with Research Centre Freising and the University of Munich to develop switches for controlling expression of transgenes in plant chloroplasts (4/11) |
Indevus |
UK government and the Medical Research Council (UK) |
£26M (US$49) |
Funding support |
For a Phase III trial in Africa of PRO 2000, the company's microbicide being developed to prevent HIV infection (4/6) |
IntegraGen SA* |
European Commission |
€12.5 (US$16) |
Funding support |
IntegraGen is part of the Euro-Hear consortium that includes 25 institutions in Europe; they will carry out research in hearing impairments (4/17) |
Integrated |
National Science Foundation |
$0.5 |
SBIR grant |
The two-year grant will support further R&D of its DNA detection technology for detecting the presence of biological agents (3/28) |
Intercell AG |
European Union |
€1.4 (US$1.8) |
Sixth Framework Program grant |
Intercell will work with five other EU institutions and firms to develop a novel vaccine against Lyme borreliosis (5/23) |
Isis |
Department of Homeland Security |
$1.5 |
Contract awards |
Isis' Ibis division got two contracts to develop microbial forensics applications of its TIGER (Triangulation Identification for Genetic Evaluation of Risks) biosensor system, as well as to enhance the system's database (4/18) |
MedPharm Ltd.* |
UK Biotechnology and Biological Sciences Research Council |
ND |
Grant |
The grant will support development of a topical system for delivering drugs to the nails for treating the fungal infection onchomyosis (4/14) |
Metabolon Inc.* |
National Institute of Environmental Health Sciences |
ND |
SBIR grant |
Metabolon will use its metabolomics platform to test plasma samples from amyotrophic lateral sclerosis patients to identify biomarkers for ALS (4/12) |
Migenix Inc. |
Canadian government |
C$9.3 (US$7.4) |
Technology Partnerships Canada investment |
TPC will invest up to C$9.3M for development related to MX-2401, a lipopeptide in preclinical development for treating bacterial infections (4/1) |
Perlegen |
National Institute of Allergy and Infectious Diseases |
ND |
Biodefense Partnership grant |
Perlegen will analyze the genomes of about 150 Yersinia pestis (which cause the plague) and Y. pseudotuberculosis strains to help distinguish the strains and understand their biology (4/4) |
Pharmos Corp. |
Israel Ministry of Industry and Trade |
$1.3 |
Office of the Chief Scientist grant |
The funds will support development of drug candidates from the company's CB2-selective platform of synthetic cannabinoids (5/2) |
Polydex |
Bill & Melinda Gates Foundation and the U.S. Agency for International Development |
$24 |
The foundation gave $12M and USAID matched the grant for trials of a microbicide to prevent HIV |
The CONRAD program of EVMS got the grant; the product is partnered with Polydex; Phase III trials will be run in India and four African countries (5/3) |
Population |
The Wellcome Trust (UK) |
£1.1 (US$2) |
Grant |
Wellcome provided funding for the newly formed company to develop a method for obtaining sequence information from thou- sands of genomes simultaneously (4/20) |
PTC |
Muscular Dystrophy Association |
$1.5 |
Grant |
The award will be used to fund development of PTC124 for treating Duchenne's muscular dystrophy that is due to a nonsense mutation in the dystrophin gene (4/21) |
Saegis |
The Stanley Medical Research Institute |
$3.8 |
Funding support |
Saegis will get up to $3.8M to continue funding clinical trials of SGS518 as a treatment for the cognitive deficit that occurs in schizophrenia; SMRI provided $2M in 2004 to support Phase I trials (5/12) |
Sanaria Inc.* |
U.S. Army |
$4.09 |
R&D funding award |
The funds will support development of the company's attenuated whole-parasite malaria vaccine (5/2) |
SRI |
National Institute of General Medical Sciences |
ND |
Continued grant |
The unit of the National Institutes of Health has continued a grant to support the modeling of complex mammalian signaling networks based on signaling of the epidermal growth factor receptor using SRI's Pathway Logic analysis software (5/23) |
Various |
National Institute of Allergy and Infectious Diseases |
$27 |
Project BioShield grants and contract awards |
Grants went to Apath LLC to develop drugs for Ebola infection; NovoBiotic Pharmaceuticals LLC to develop drugs against anthrax; Nanotherapeutics Inc. to develop single-dose disposable inhalers of two antibiotics; MaxThera Inc. to identify agents against bioterror pathogens; and Veritas Inc. to develop tests used to screen drugs that inhibit the botulinum neurotoxin; contracts went to XOMA LLC to develop and produce antibodies against botulinum toxin type A; and DVC Dynport LLC to produce a vaccine against botulinum toxin type E (5/9) |
VistaGen |
National Institute of Neurologic Disorders and Stroke |
$3.7 |
Development grant |
The grant will cover the pre-clinical development of 4-C1-KYN (AV-101) in epilepsy (5/24) |
Xantos |
German Ministry for Education and Research |
ND |
BioChancePLUS program grant |
The grant will help the firms' efforts to identify and develop drugs to inhibit tumor angiogenesis, using an aptamer-based approach (4/13) |
| | ||||
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-The-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | ||||
